FDA Sued Over Novo Nordisk Weight Loss Drug Shortage Decision

Drug compounders are suing the Food and Drug Administration for improperly declaring an end to the shortage of Novo Nordisk’s weight-loss and diabetes drugs, accusing the agency of “depriving patients of much needed treatment and artificially raising drug prices.”

Led by the trade group for compounders, the Outsourcing Facilities Association, the lawsuit comes after regulators on Feb. 21 said Novo Nordisk A/S‘s blockbuster Ozempic and Wegovy drugs were no longer in short supply.

That means most so-called drug compounders—pharmacists, facilties, and others who mix ingredients to create medications in shortages—must stop producing copies of the drugs.

The compounders, however, ...